Another example is transthyretin amyloidosis, caused by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, for which the systemic injection of lipid nanoparticle encapsulating messenger RNA for Cas9 protein and a single guide RNA targeting TTR, leading to DNA cleavage of the TTR to prevent the production of the misfolded TTR protein, is currently being evaluated in a phase 1 trial (ClinicalTrials.gov number, NCT04601051). This evidence concerns the gene TTR and amyloidosis.